<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Infect Dis Rep</journal-id><journal-id journal-id-type="iso-abbrev">Infect Dis Rep</journal-id><journal-id journal-id-type="publisher-id">idr</journal-id><journal-title-group><journal-title>Infectious Disease Reports</journal-title></journal-title-group><issn pub-type="ppub">2036-7430</issn><issn pub-type="epub">2036-7449</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40407641</article-id><article-id pub-id-type="pmc">PMC12101312</article-id>
<article-id pub-id-type="doi">10.3390/idr17030039</article-id><article-id pub-id-type="publisher-id">idr-17-00039</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Diagnostic Challenges in Extrapulmonary Tuberculosis: A Single-Center Experience in a High-Resource Setting at a German Tertiary Care Center</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Wilmink</surname><given-names>Jonas</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-idr-17-00039" ref-type="aff">1</xref><xref rid="fn1-idr-17-00039" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-3208-7924</contrib-id><name><surname>Vollenberg</surname><given-names>Richard</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-idr-17-00039" ref-type="aff">1</xref><xref rid="fn1-idr-17-00039" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Olaru</surname><given-names>Ioana D.</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af2-idr-17-00039" ref-type="aff">2</xref><xref rid="af3-idr-17-00039" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6138-7454</contrib-id><name><surname>Fischer</surname><given-names>Julia</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af1-idr-17-00039" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Trebicka</surname><given-names>Jonel</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-idr-17-00039" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-2757-4755</contrib-id><name><surname>Tepasse</surname><given-names>Phil-Robin</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-idr-17-00039" ref-type="aff">1</xref><xref rid="c1-idr-17-00039" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-idr-17-00039"><label>1</label>Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital M&#x000fc;nster, 48149 M&#x000fc;nster, Germany; <email>jonas.wilmink@ukmuenster.de</email> (J.W.); <email>richard.vollenberg@ukmuenster.de</email> (R.V.); <email>julia.fischer2@ukmuenster.de</email> (J.F.); <email>jonel.trebicka@ukmuenster.de</email> (J.T.)</aff><aff id="af2-idr-17-00039"><label>2</label>Institute of Medical Microbiology, University Hospital M&#x000fc;nster, 48149 M&#x000fc;nster, Germany</aff><aff id="af3-idr-17-00039"><label>3</label>Clinical Research Department, London School of Hygiene &#x00026; Tropical Medicine, London WC1E 7HT, UK</aff><author-notes><corresp id="c1-idr-17-00039"><label>*</label>Correspondence: <email>phil-robin.tepasse@ukmuenster.de</email></corresp><fn id="fn1-idr-17-00039"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>23</day><month>4</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><volume>17</volume><issue>3</issue><elocation-id>39</elocation-id><history><date date-type="received"><day>11</day><month>2</month><year>2025</year></date><date date-type="rev-recd"><day>29</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>14</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p><bold>Background/Objectives</bold>: Extrapulmonary tuberculosis accounts for a significant portion of tuberculosis cases, presenting unique diagnostic challenges due to its heterogeneous manifestations and paucibacillary nature. This study aims to fill this gap by evaluating the diagnostic outcomes and correlations between different specimen types and test results. <bold>Methods</bold>: A retrospective analysis of electronic medical records of patients diagnosed with TB between January 2013 and December 2023 was carried out. The data extracted included patient demographics, comorbidities, TB classification, specimen types, microbiological test results, and time intervals to diagnosis. Statistical analysis was applied to compare the variables between pulmonary and extrapulmonary/disseminated TB groups. <bold>Results</bold>: Most patients were male (62.4%) and born outside of Germany (74.2%). Comorbidities, such as diabetes, cardiac disease, immunosuppressed status, and HIV, were common. Among the 194 patients, 98 had pulmonary TB, and 96 had extrapulmonary/disseminated TB. A comparison of pulmonary vs. extrapulmonary TB showed that extrapulmonary TB patients had a longer diagnostic delay (<italic toggle="yes">p</italic> = 0.013), more symptoms (<italic toggle="yes">p</italic> = 0.001), and more complications (42.7% vs. 16.3%, <italic toggle="yes">p</italic> &#x0003c; 0.001). Diagnostic challenges were evident, with multiple invasive procedures required in 43.5% of the extrapulmonary TB cases. <bold>Conclusions</bold>: This study highlights the complex clinical presentation of tuberculosis, particularly in patients with extrapulmonary and disseminated forms, who experience delayed diagnosis and more complications. These challenges in diagnosing extrapulmonary TB emphasize the need for improved diagnostic strategies and early identification, especially in high-risk populations.</p></abstract><kwd-group><kwd>extrapulmonary tuberculosis</kwd><kwd>acid-fast bacilli</kwd><kwd>diagnostic challenges</kwd><kwd>disseminated tuberculosis</kwd><kwd>complications</kwd><kwd><italic toggle="yes">Mycobacterium tuberculosis</italic></kwd></kwd-group><funding-group><funding-statement>This research received no external funding.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-idr-17-00039"><title>1. Introduction</title><p>Extrapulmonary tuberculosis (EPTB) represents a significant and increasingly prevalent subset of tuberculosis (TB) cases worldwide. The World Health Organization estimates that approximately 15% of all TB cases are EPTB, with higher proportions reported in HIV-positive individuals [<xref rid="B1-idr-17-00039" ref-type="bibr">1</xref>]. In Europe, around a quarter of patients with TB have extrapulmonary involvement [<xref rid="B2-idr-17-00039" ref-type="bibr">2</xref>], with migrants, especially those from Southeast Asia and Africa, being more likely to suffer from EPTB [<xref rid="B3-idr-17-00039" ref-type="bibr">3</xref>,<xref rid="B4-idr-17-00039" ref-type="bibr">4</xref>]. In Germany, 24% of patients have EPTB, the vast majority of whom are born outside the country [<xref rid="B5-idr-17-00039" ref-type="bibr">5</xref>]. Despite this growing burden, EPTB remains underdiagnosed and underreported due to several unique challenges associated with its diagnosis.</p><p>The clinical presentation of EPTB is diverse and often nonspecific, making it difficult to distinguish it from other infectious or inflammatory diseases. Furthermore, the bacteriological confirmation of <italic toggle="yes">Mycobacterium tuberculosis</italic> in extrapulmonary specimens can be challenging due to their paucibacillary nature and difficulty in obtaining suitable samples [<xref rid="B6-idr-17-00039" ref-type="bibr">6</xref>]. Acid-fast bacilli (AFP) smear microscopy has low sensitivity for EPTB, while for nucleic acid amplification tests, like Xpert MTB/RIF and cultures, the sensitivity is variable depending on the site affected [<xref rid="B7-idr-17-00039" ref-type="bibr">7</xref>,<xref rid="B8-idr-17-00039" ref-type="bibr">8</xref>,<xref rid="B9-idr-17-00039" ref-type="bibr">9</xref>,<xref rid="B10-idr-17-00039" ref-type="bibr">10</xref>,<xref rid="B11-idr-17-00039" ref-type="bibr">11</xref>].</p><p>While AFB staining offers rapid results, it has poor sensitivity, ranging between 20% and 50%, depending on the sample type [<xref rid="B11-idr-17-00039" ref-type="bibr">11</xref>]. Culture-based methods serve as reference standards for mycobacterial infection confirmation; however, their turnaround time ranges from two to eight weeks, resulting in protracted diagnosis periods and compromised patient outcomes. Nucleic acid amplification tests (NAATs) are increasingly recognized for their superior performance characteristics, such as faster turnaround times and enhanced sensitivity, and significant progress is being made to expand their availability, even in resource-constrained settings [<xref rid="B11-idr-17-00039" ref-type="bibr">11</xref>,<xref rid="B12-idr-17-00039" ref-type="bibr">12</xref>].</p><p>Imaging techniques, such as computed tomography and magnetic resonance imaging, play crucial roles in guiding clinicians toward appropriate diagnostic workups; however, they cannot definitively confirm EPTB [<xref rid="B13-idr-17-00039" ref-type="bibr">13</xref>,<xref rid="B14-idr-17-00039" ref-type="bibr">14</xref>,<xref rid="B15-idr-17-00039" ref-type="bibr">15</xref>]. Lastly, biopsy and histopathology remain essential tools for diagnosing EPTB but require invasive procedures and expertise for interpretation [<xref rid="B16-idr-17-00039" ref-type="bibr">16</xref>,<xref rid="B17-idr-17-00039" ref-type="bibr">17</xref>].</p><p>The aim of this study was to describe the characteristics of patients with EPTB presenting to a tertiary care referral hospital in Germany and to highlight the challenges of diagnosing EPTB in a high-resource setting with advanced diagnostic tools, emphasizing the need for tailored approaches to improve diagnostic accuracy and patient outcomes.</p></sec><sec id="sec2-idr-17-00039"><title>2. Materials and Methods</title><p>This study was conducted at the University Hospital M&#x000fc;nster, a tertiary care center in Germany. Electronic medical records from patients admitted between 2013 and 2023 with microbiologically confirmed active TB were retrieved. Data extracted from the records included demographic information, clinical details, and laboratory results related to the diagnosis and management of TB. Molecular methods used for TB detection included Xpert MTB/RIF Ultra (Cepheid, Sunnyvale, CA, USA) for native samples and an in-house nested polymerase chain reaction for formalin-fixed samples. All procedures followed institutional ethical guidelines, ensuring patient confidentiality and compliance with data protection regulations. This study received ethical approval from the local ethics committee at Muenster University Hospital (Approval number: 2020-566-f-S).</p><sec><title>Statistical Analyses</title><p>For categorical variables, data were presented as counts and percentages, with comparisons made using either the chi-square test or Fisher&#x02019;s exact test. Continuous variables were reported as medians with interquartile ranges (IQR) or as minimum and maximum values, with comparisons performed using either the Student&#x02019;s <italic toggle="yes">t</italic>-test or the Mann&#x02013;Whitney U test, depending on the data distribution. All statistical tests were two-tailed, and a <italic toggle="yes">p</italic>-value of less than 0.05 was considered statistically significant. SPSS version 26 (IBM, Chicago, IL, USA) was used for all statistical analyses.</p></sec></sec><sec sec-type="results" id="sec3-idr-17-00039"><title>3. Results</title><sec id="sec3dot1-idr-17-00039"><title>3.1. Patients Characteristics</title><p>A total of 194 patients were identified as diagnosed with TB and included in the study. The median age was 41 years, with a range of 16 to 89 years. Among them, 121/194 (62.4%) were males, and most had been born outside Germany (74.2%). For details of the country distribution, see <xref rid="app1-idr-17-00039" ref-type="app">Supplemental Table S1</xref>.</p><p>Regarding comorbidities, diabetes mellitus affected 9.8% of patients, cardiac disease was present in 21.6%, pulmonary disease in 14.4%, HIV infection in 9.3%, replicating hepatitis C infection in 4.1% (detection of Hep. C RNA in peripheral blood), replicating hepatitis B infection in 2.6% (detection of Hep. B DNA in peripheral blood), organ transplant recipients accounted for 3.6%, hematologic disease occurred in 3.1%, and autoimmune disease was found in 8.2%. Nearly one-fifth (18.6%) received immunosuppressive therapy.</p><p>Considering the site of TB infection, isolated pulmonary involvement was observed in 50.5%, disseminated infection with more than one infection site in 21.1%, isolated lymph node involvement in 16%, isolated bone TB in 5.2%, abdominal, urogenital, intestinal, cerebral, soft tissue, and cardiovascular TB each represented less than 5.2%.</p><p>A total of 10 patients (5.2%) suffered from multi-drug-resistant tuberculosis (MDR-TB), three (1.5%) presented with pre-XDR tuberculosis, and three (1.5%) with extensively drug-resistant tuberculosis (XDR-TB). Therapy outcomes were not evaluated for 119 (61.3%) of the patients due to loss of follow-up, whereas sustained treatment success was achieved in 55 cases (28.4%) (as defined before [<xref rid="B18-idr-17-00039" ref-type="bibr">18</xref>]). Unfortunately, three patients (1.5%) died during therapy, and 17 (8.8%) continued receiving treatment at the study cutoff (see <xref rid="idr-17-00039-t001" ref-type="table">Table 1</xref>).</p></sec><sec id="sec3dot2-idr-17-00039"><title>3.2. Clinical and Diagnostic Differences Between Isolated Pulmonary and Extrapulmonary/Disseminated Tuberculosis: A Comparative Analysis</title><p>Next, a comparative analysis was conducted between patients with isolated pulmonary tuberculosis (<italic toggle="yes">n</italic> = 98) and those with extrapulmonary/disseminated tuberculosis (<italic toggle="yes">n</italic> = 96). The median age of patients in the pulmonary group was 44.5 years, whereas it was 35 years in the extrapulmonary/disseminated group, though this difference was not statistically significant (<italic toggle="yes">p</italic> = 0.24). Fewer patients with extrapulmonary/disseminated TB were of German origin (19.7% vs. 31.6%, <italic toggle="yes">p</italic> = 0.049).</p><p>Symptomatic disease was more prevalent in the extrapulmonary/disseminated tuberculosis group (85.4%, <italic toggle="yes">n</italic> = 82) compared to the pulmonary group (65.3%, <italic toggle="yes">n</italic> = 64), with a highly significant difference (<italic toggle="yes">p</italic> = 0.001). In patients with isolated lung disease, the diagnosis was made following contact tracing in 34 cases versus 14 cases in the other group (<italic toggle="yes">p</italic> = 0.001).</p><p>General symptoms such as fever, night sweats, and weight loss were observed with similar frequencies in both groups (<italic toggle="yes">p</italic> &#x0003e; 0.05). However, specific symptoms varied significantly depending on the form of tuberculosis. Pulmonary tuberculosis was more frequently associated with cough (82.8% vs. 11%, <italic toggle="yes">p</italic> &#x0003c; 0.001), hemoptysis (10.9% vs. 0%, <italic toggle="yes">p</italic> = 0.003), and thoracic pain (15.6% vs. 2.4%, <italic toggle="yes">p</italic> = 0.005). In contrast, patients with extrapulmonary/disseminated tuberculosis more commonly presented with lymph node swelling (43.9% vs. 0%, <italic toggle="yes">p</italic> &#x0003c; 0.001), abdominal pain (23.2% vs. 1.6%, <italic toggle="yes">p</italic> &#x0003c; 0.001), bone pain (22% vs. 1.6%, <italic toggle="yes">p</italic> &#x0003c; 0.001), and headache (8.5% vs. 0%, <italic toggle="yes">p</italic> = 0.018) (see <xref rid="app1-idr-17-00039" ref-type="app">Supplemental Table S2</xref>).</p><p>Additionally, the median time interval from the first physician contact to tuberculosis diagnosis was longer in the extrapulmonary/disseminated group, with a range extending up to 208 weeks, compared to just 8 weeks in the pulmonary group (<italic toggle="yes">p</italic> = 0.013).</p><p>In this study, the prevalence of HIV infection was comparable between patients with pulmonary tuberculosis (10.2%) and extrapulmonary tuberculosis (8.3%) (<italic toggle="yes">p</italic> = 0.81). Median CD4<sup>+</sup> cell counts were lower in extrapulmonary tuberculosis patients (126.5 cells/&#x000b5;L, IQR: 44.25&#x02013;225.75) compared to pulmonary tuberculosis patients (264.0 cells/&#x000b5;L, IQR: 84.75&#x02013;442.0), though this difference was not statistically significant (<italic toggle="yes">p</italic> = 0.21). Antiretroviral therapy (ART) coverage was significantly higher in pulmonary tuberculosis patients (60%) compared to those with extrapulmonary tuberculosis (12.5%) (<italic toggle="yes">p</italic> = 0.04).</p><p>Among patients with pulmonary tuberculosis, seven (7.1%) had a hepatitis C infection, with four (57.1%) showing detectable hepatitis C RNA. In the extrapulmonary tuberculosis group, five patients (5.2%) had a hepatitis C infection, and four (80%) had detectable viral RNA. Notably, none of the patients had relevant liver dysfunction.</p><p>Patients with pulmonary TB more frequently had a positive smear microscopy for acid-fast bacilli: 40.8% vs. 13.5% among those with EPTB (<italic toggle="yes">p</italic> &#x0003c; 0.001), and a positive <italic toggle="yes">M. tuberculosis</italic> NAAT (74.5% vs. 29.2%, <italic toggle="yes">p</italic> &#x0003c; 0.001). Patients with extrapulmonary/disseminated tuberculosis experienced more frequent disease-associated complications (42.7% vs. 16.3%, <italic toggle="yes">p</italic> &#x0003c; 0.001), including sepsis (9.4% vs. 2%, <italic toggle="yes">p</italic> = 0.03), paradoxical immune reactions (8.3% vs. 0%, <italic toggle="yes">p</italic> = 0.003), and the need for surgical interventions (11.5% vs. 0%, <italic toggle="yes">p</italic> &#x0003c; 0.001). For details, see <xref rid="idr-17-00039-t002" ref-type="table">Table 2</xref>.</p></sec><sec sec-type="methods" id="sec3dot3-idr-17-00039"><title>3.3. Diagnostic Yield and Procedures in Extrapulmonary/Disseminated Tuberculosis</title><p>This study involved 96 patients with extrapulmonary or disseminated TB, and tissue samples were obtained from 92 (95.8%) of the cases for diagnostic purposes. Notably, in 43.5% of the patients (<italic toggle="yes">n</italic> = 40), more than one invasive procedure was required to confirm the microbiological presence of the pathogen because the TB diagnosis was not initially suspected. The sites of specimen collection were lymph nodes (<italic toggle="yes">n</italic> = 41, 44.6%), bones (<italic toggle="yes">n</italic> = 15, 16.3%), soft tissue (<italic toggle="yes">n</italic> = 10, 10.9%), colon (<italic toggle="yes">n</italic> = 5, 5.4%), bone marrow (<italic toggle="yes">n</italic> = 4, 4.3%), brain (<italic toggle="yes">n</italic> = 4, 4.3%), urine (<italic toggle="yes">n</italic> = 4, 4.3%), stool (<italic toggle="yes">n</italic> = 2, 2.1%), liver (<italic toggle="yes">n</italic> = 2, 2.2%), blood culture (<italic toggle="yes">n</italic> = 2, 2.2%), pericardium (<italic toggle="yes">n</italic> = 2, 2.2%), and ascitic fluid (<italic toggle="yes">n</italic> = 1, 1.1%).</p><p>A histologic analysis was conducted in 68 cases (73.9%) and revealed epithelioid granulomas in 59 of these cases (86.8%). NAAT on formalin-fixed specimens was performed in 55 cases (59.8%), with 44 of these (80%) showing a positive result for <italic toggle="yes">M. tuberculosis</italic> DNA.</p><p>A microscopic analysis for acid-fast bacilli on native (non-formalin-fixed) specimens was performed in 78 cases (84.8%), and acid-fast bacilli were detected in 22 cases (28.2%). Additionally, the NAAT analysis of these 78 native specimens revealed MTB DNA positivity in 59 cases (75.6%). The TB culture was positive in 56 cases (71.8%) (for details see <xref rid="idr-17-00039-t003" ref-type="table">Table 3</xref>).</p></sec><sec id="sec3dot4-idr-17-00039"><title>3.4. Diagnostic Performance of Microbiological MTB Detection Methods Across Various Specimen Types</title><p>The diagnostic performance of the MTB culture, PCR on primary specimens, and microscopy on primary specimens varied across different specimen types. In lymph node biopsies (<italic toggle="yes">n</italic> = 31), the PCR demonstrated the highest positivity rate at 87.1%, followed by the culture at 77.4%, while microscopy was less sensitive with a positivity rate of 25.8%. For bone biopsies (<italic toggle="yes">n</italic> = 15), the culture showed a high positivity rate of 86.7%, whereas the PCR was positive in 60% of cases, and microscopy was only positive in 26.7%. For details, see <xref rid="idr-17-00039-t004" ref-type="table">Table 4</xref>.</p></sec></sec><sec sec-type="discussion" id="sec4-idr-17-00039"><title>4. Discussion</title><p>Our results indicate that the majority of patients in our tertiary care center diagnosed with TB were male, middle-aged adults who were born outside of Germany, and comorbidities, such as diabetes, cardiac disease, pulmonary disease, and immunosuppression, were common. This finding aligns with previous research, suggesting that older age [<xref rid="B19-idr-17-00039" ref-type="bibr">19</xref>], male gender [<xref rid="B20-idr-17-00039" ref-type="bibr">20</xref>,<xref rid="B21-idr-17-00039" ref-type="bibr">21</xref>], underlying health conditions, such as chronic lung disease [<xref rid="B22-idr-17-00039" ref-type="bibr">22</xref>], immunosuppression [<xref rid="B23-idr-17-00039" ref-type="bibr">23</xref>,<xref rid="B24-idr-17-00039" ref-type="bibr">24</xref>], and birth in a low-income country, increase the risk of developing active TB [<xref rid="B25-idr-17-00039" ref-type="bibr">25</xref>,<xref rid="B26-idr-17-00039" ref-type="bibr">26</xref>]. Interestingly, our data also revealed that diabetes mellitus was a frequently found comorbidity affecting close to ten percent of the patients. Previous studies have shown that diabetes significantly increases the likelihood of developing active TB [<xref rid="B27-idr-17-00039" ref-type="bibr">27</xref>,<xref rid="B28-idr-17-00039" ref-type="bibr">28</xref>]. Patients with medication-induced immunosuppression, organ transplantation, hematologic-oncologic diseases, and HIV were frequently treated at our tertiary care center. These patients are at an increased risk for tuberculosis infection and reactivation of latent TB, as immunosuppressive therapies can trigger reactivation or disease progression, with EPTB being more common. Although latent TB infection (LTBI) screening is routine before starting immunosuppression, clinicians should remain alert for TB even after screening.</p><p>Furthermore, our analysis showed that disseminated infection and extrapulmonary involvement were common among TB patients, accounting for more than half of the cases. Lymph node involvement was the most frequently observed extrapulmonary manifestation, similar to earlier observations [<xref rid="B29-idr-17-00039" ref-type="bibr">29</xref>,<xref rid="B30-idr-17-00039" ref-type="bibr">30</xref>,<xref rid="B31-idr-17-00039" ref-type="bibr">31</xref>,<xref rid="B32-idr-17-00039" ref-type="bibr">32</xref>]. However, bone and joint TB, as well as central nervous system involvement, were infrequently observed.</p><p>Our findings comparing isolated pulmonary TB and EPTB reveal notable variations in clinical presentation, diagnostic modalities, and complications. These distinctions correspond to the trends documented in previous literature. Our study found no statistically significant difference in the median age between the pulmonary and extrapulmonary TB groups, although there was a slight trend toward younger patients in the extrapulmonary/disseminated group (35 years vs. 44.5 years). These findings are consistent with previous studies that have suggested a younger age distribution in extrapulmonary TB, although some studies report a wider age range, especially in regions with a high TB burden [<xref rid="B1-idr-17-00039" ref-type="bibr">1</xref>]. The lower proportion of patients of German origin among those with EPTB (19.7% vs. 31.6%) is an interesting observation, potentially reflecting the higher prevalence of extrapulmonary TB in some populations, particularly in countries with a high TB incidence [<xref rid="B30-idr-17-00039" ref-type="bibr">30</xref>,<xref rid="B31-idr-17-00039" ref-type="bibr">31</xref>].</p><p>A key finding in our study was the significantly higher prevalence of symptomatic disease in the extrapulmonary/disseminated group (85.4%) compared to the pulmonary group (65.3%). This is in line with previous research that has shown that extrapulmonary TB often presents with more varied and nonspecific symptoms, leading to a higher likelihood of symptomatic disease at presentation [<xref rid="B33-idr-17-00039" ref-type="bibr">33</xref>,<xref rid="B34-idr-17-00039" ref-type="bibr">34</xref>,<xref rid="B35-idr-17-00039" ref-type="bibr">35</xref>]. Extrapulmonary TB can affect multiple organ systems, making it more likely to be symptomatic and harder to diagnose early, particularly in settings where TB screening is not routine [<xref rid="B36-idr-17-00039" ref-type="bibr">36</xref>]. Consequently, our study revealed a significant diagnostic delay observed in the extrapulmonary TB group compared to the pulmonary group. Delayed diagnosis in EPTB is well documented, as patients may present with nonspecific symptoms, or the disease may not be suspected initially, particularly in the absence of pulmonary involvement. In contrast, pulmonary TB is often diagnosed earlier due to more characteristic symptoms, such as cough, hemoptysis, and chest pain, as well as the availability of routine screening in certain populations. Our study also found that only 28.1% of patients with EPTB had concurrent pulmonary involvement. Only 14.6% of these patients were diagnosed as a result of screening. In summary, these data suggest that the manifestations of extrapulmonary tuberculosis can be easily overlooked due to the lack of screening, especially since the focus of currently available screening programs in most countries is on detecting the contagious pulmonary form of the disease [<xref rid="B1-idr-17-00039" ref-type="bibr">1</xref>,<xref rid="B34-idr-17-00039" ref-type="bibr">34</xref>,<xref rid="B37-idr-17-00039" ref-type="bibr">37</xref>].</p><p>Our findings also revealed that patients with extrapulmonary/disseminated TB had a significantly higher rate of disease-associated complications (42.7% vs. 16.3%, <italic toggle="yes">p</italic> &#x0003c; 0.001), including sepsis, paradoxical immune reactions, and the need for operative procedures. The higher frequency of TBC bacteremia in the extrapulmonary group may reflect the systemic nature of the disease, as disseminated TB can affect multiple organ systems and predispose patients to secondary infections [<xref rid="B34-idr-17-00039" ref-type="bibr">34</xref>]. Paradoxical immune reactions, seen in 8.3% of patients in the extrapulmonary group, are another well-documented complication, particularly in patients with disseminated or HIV-associated TB. Such immune responses often occur after the initiation of anti-TB therapy and may complicate the clinical course [<xref rid="B38-idr-17-00039" ref-type="bibr">38</xref>,<xref rid="B39-idr-17-00039" ref-type="bibr">39</xref>,<xref rid="B40-idr-17-00039" ref-type="bibr">40</xref>]. The need for surgical interventions in a significant number of patients also highlights the difficulties in EPTB therapy and diagnosis. Surgical interventions, such as drainage of abscesses or biopsy for histopathological evaluation, are often required to manage complications or confirm the diagnosis in EPTB, further complicating patient care. Notably, in 43.5% of the patients, more than one procedure (including biopsies, punctures, and operative procedures) was required to confirm the microbiological presence of the pathogen. Tuberculosis was not initially suspected during the first procedure in these cases, and the samples were fixed only in formalin. As a result, a second procedure was necessary to obtain native, unfixed specimens for microbiological and, particularly, cultural pathogen confirmation.</p><p>Our study shows a significantly lower proportion of patients on combined antiretroviral therapy (cART) in the extrapulmonary tuberculosis (EPTB) group (12.5% vs. 60%). This may be linked to limited healthcare access, as more patients in this group originated from non-German countries. The lower cART coverage could explain the trend toward lower CD4<sup>+</sup> counts (median 126.5 vs. 264.0 cells/&#x000b5;L), even though this difference was not statistically significant (<italic toggle="yes">p</italic> = 0.21). Severe immunosuppression due to delayed cART initiation may have contributed to the higher occurrence of extrapulmonary and disseminated TB. These findings highlight the need for improved HIV care access, particularly for migrants from low-resource settings.</p><p>Our study employed several diagnostic techniques, each with varying yields depending on the specimen type. Histological analysis, conducted in 73.9% of the cases, identified epithelioid granulomas in 86.8% of the samples. Although granulomas are suggestive of tuberculosis, they are not pathognomonic, as they can also be found in other conditions, such as sarcoidosis or fungal infections. Nonetheless, granulomas remain a key diagnostic clue in extrapulmonary TB, warranting further microbiological testing. NAAT analysis on formalin-fixed specimens yielded an 80% positivity for MTB DNA, confirming the utility of this method as a sensitive and rapid tool for detecting TB, even in suboptimal samples. However, the variability of NAAT across specimen types&#x02014;such as formalin-fixed versus native samples&#x02014;highlights its limitations in complex cases like EPTB. Microscopy was performed in 84.8% of the native specimens, with AFB detected in only 28.2%. This low yield is consistent with the generally lower bacterial load in EPTB compared to pulmonary TB, reducing the sensitivity of microscopy [<xref rid="B41-idr-17-00039" ref-type="bibr">41</xref>]. Unsurprisingly, microscopy had a low yield, while culture and NAAT were positive in more than 70% of the patients [<xref rid="B41-idr-17-00039" ref-type="bibr">41</xref>]. Finally, culture positivity was 71.8% in the native specimens, reinforcing the value of culture as the gold standard for TB diagnosis. While culture remains definitive, its time-consuming nature emphasizes the importance of using faster adjuncts like PCR and histology, especially in cases of suspected disseminated TB. Different native tissue samples exhibit varying sensitivities for tuberculosis detection via PCR. Our study reveals notable variations in TB culture positivity across specimen types: lymph node biopsies showed a 77.4% positivity rate, and bone biopsies showed 86.7%. Although other specimen types also yielded positive results, small sample sizes suggest a cautious interpretation of generalizability. Different native tissue samples exhibit varying sensitivities for tuberculosis detection via NAAT [<xref rid="B11-idr-17-00039" ref-type="bibr">11</xref>,<xref rid="B42-idr-17-00039" ref-type="bibr">42</xref>,<xref rid="B43-idr-17-00039" ref-type="bibr">43</xref>]. These findings underscore the potential of AFB and PCR as early indicators of active TB, especially where rapid culture results are unavailable.</p><p>One limitation of our study is that our institution serves as a major referral center for tuberculosis cases in M&#x000fc;nster and the M&#x000fc;nsterland region in West-Germany, receiving patients not only from local healthcare providers but also from primary reception facilities for migrants. Given its role as a specialized center, our cohort may not fully reflect the TB epidemiology of the general population but rather a subset of patients with more complex or severe presentations. We will include a description of this in the Methods section to clarify the study&#x02019;s scope and applicability. A further limitation of our retrospective analysis is the potential use of different diagnostic and clinical assessment protocols for extrapulmonary TB (EPTB). Since the data collection spanned an extended period, institutional or temporal variations in diagnostic approaches and treatment strategies may have influenced the results, potentially limiting their comparability. Prospective studies with standardized assessment protocols would be necessary to provide a more precise evaluation of EPTB cases. Furthermore, due to the retrospective nature of our study, we were unable to systematically assess patient adherence to TB therapy or long-term outcomes after treatment completion. This limits our ability to evaluate treatment success and the risk of recurrence. Additionally, there is a risk of incomplete or missing data, particularly regarding follow-up documentation. A significant proportion of our cohort consisted of migrants who were initially referred to our tertiary care center from primary reception facilities. Many of these patients were later transferred to other healthcare institutions within Germany or repatriated to their home countries, making long-term follow-up challenging. Due to administrative and logistical barriers, including changes in residence status and limited access to updated contact information, continued monitoring was often not feasible. Future studies should explore strategies to improve patient tracking and inter-institutional communication to minimize losses to follow-up in similar populations.</p><p>Our results indicate that, despite a high-resource setting, optimizing local Standard Operating Procedures (SOPs) and targeted staff training could significantly improve TB care. Strengthening institutional workflows and increasing awareness among healthcare workers are key factors in order to avoid diagnostic delays, unnecessary multiple interventions for sample collection, and improving treatment outcomes. Based on our findings, we propose the following locally focused measures:
<list list-type="simple"><list-item><p><underline>Enhanced Diagnostic Strategies</underline>:</p></list-item></list></p><p>Ensure the implementation of hospital-wide screening protocols for high-risk patients, particularly those undergoing immunosuppressive therapy.</p><p>Standardize specimen handling procedures through internal SOPs and staff workshops to ensure optimal microbiological diagnostics (e.g., avoiding formalin fixation for cultures).</p><p>Promote the routine use of NAAT and imaging (CT/MRI) for early EPTB detection, supported by radiology training sessions on TB-specific findings.
<list list-type="simple"><list-item><p><underline>Improved Treatment Approaches</underline>:</p></list-item></list></p><p>Establish interdisciplinary case discussions (infectious diseases, pulmonology, radiology, and surgery) to optimize decision-making in TB management.</p><p>Strengthen internal hospital protocols for early cART initiation in HIV patients through close cooperation between infectious disease specialists and primary care providers.</p><p>Develop training modules for clinicians on recognizing and managing surgical indications in EPTB cases.
<list list-type="simple"><list-item><p><underline>Strengthening Follow-up</underline>:</p></list-item></list></p><p>Improve coordination with local public health authorities and primary care physicians through structured communication pathways and regular feedback meetings.</p></sec><sec sec-type="conclusions" id="sec5-idr-17-00039"><title>5. Conclusions</title><p>Our study highlights the challenges in diagnosing and managing TB, particularly extrapulmonary and disseminated forms, even in a high-resource setting. Despite advanced diagnostic tools, delays in detection and treatment remain a concern, emphasizing the need for optimized local Standard Operating Procedures. A structured, hospital-based approach, including enhanced screening, standardized diagnostic workflows, continuous staff training, and interdisciplinary case discussions, can significantly improve TB care. Ensuring closer collaboration with public health authorities, primary care providers, and external healthcare facilities will be essential in preventing losses to follow-up and improving long-term patient management, particularly in vulnerable patient populations.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-idr-17-00039"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/idr17030039/s1">https://www.mdpi.com/article/10.3390/idr17030039/s1</uri>, Supplemental Table S1: Countries of origin of the whole study cohort; Supplemental Table S2: Comparison of clinical symptoms between symptomatic patients with isolated pulmonary tuberculosis (<italic toggle="yes">n</italic> = 64) and those with extrapulmonary/disseminated tuberculosis (<italic toggle="yes">n</italic> = 82). Significant differences are highlighted by <italic toggle="yes">p</italic>-values &#x0003c; 0.05.</p><supplementary-material id="idr-17-00039-s001" position="float" content-type="local-data"><media xlink:href="idr-17-00039-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization, J.W. and P.-R.T.; formal analysis, J.W. and R.V.; methodology, J.W., R.V. and P.-R.T.; supervision, J.T. and P.-R.T.; validation, I.D.O. and J.F.; writing&#x02014;original draft, J.W., R.V. and P.-R.T.; writing&#x02014;review and editing, J.W., R.V., I.D.O., J.F., J.T. and P.-R.T. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>This study was conducted in accordance with the Declaration of Helsinki and approved by the local ethics committee at Muenster University Hospital (Amendment to protocol code 2020-566-f-S, date of approval: 6 April 2024).</p></notes><notes><title>Informed Consent Statement</title><p>Patient consent was waived due to the retrospective study design with the approval of the local ethic committee.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The data are unavailable due to patients&#x02019; privacy.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-idr-17-00039"><label>1.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>World Health Organization</collab>
</person-group><source>Global Tuberculosis Report 2020</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2020</year></element-citation></ref><ref id="B2-idr-17-00039"><label>2.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>European Centre for Disease Prevention and Control</collab>
</person-group><source>Tuberculosis. ECDC. Annual Epidemiological Report for 2022</source><publisher-name>ECDC</publisher-name><publisher-loc>Solna, Sweden</publisher-loc><year>2024</year></element-citation></ref><ref id="B3-idr-17-00039"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kunst</surname><given-names>H.</given-names></name>
<name><surname>Lange</surname><given-names>B.</given-names></name>
<name><surname>Hovardovska</surname><given-names>O.</given-names></name>
<name><surname>Bockey</surname><given-names>A.</given-names></name>
<name><surname>Zenner</surname><given-names>D.</given-names></name>
<name><surname>Andersen</surname><given-names>A.B.</given-names></name>
<name><surname>Hargreaves</surname><given-names>S.</given-names></name>
<name><surname>Pareek</surname><given-names>M.</given-names></name>
<name><surname>Friedland</surname><given-names>J.S.</given-names></name>
<name><surname>Wejse</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Tuberculosis in adult migrants in Europe: A TBnet consensus statement</article-title><source>Eur. Respir. J.</source><year>2025</year><volume>65</volume><fpage>2401612</fpage><pub-id pub-id-type="doi">10.1183/13993003.01612-2024</pub-id><pub-id pub-id-type="pmid">39672603</pub-id>
</element-citation></ref><ref id="B4-idr-17-00039"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rachwal</surname><given-names>N.</given-names></name>
<name><surname>Idris</surname><given-names>R.</given-names></name>
<name><surname>Dreyer</surname><given-names>V.</given-names></name>
<name><surname>Richter</surname><given-names>E.</given-names></name>
<name><surname>Wichelhaus</surname><given-names>T.A.</given-names></name>
<name><surname>Niemann</surname><given-names>S.</given-names></name>
<name><surname>Wetzstein</surname><given-names>N.</given-names></name>
<name><surname>Gotsch</surname><given-names>U.</given-names></name>
</person-group><article-title>Pathogen and host determinants of extrapulmonary tuberculosis among 1035 patients in Frankfurt am Main, Germany, 2008&#x02013;2023</article-title><source>Clin. Microbiol. Infect.</source><year>2025</year><volume>31</volume><fpage>425</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1016/j.cmi.2024.11.009</pub-id><pub-id pub-id-type="pmid">39528087</pub-id>
</element-citation></ref><ref id="B5-idr-17-00039"><label>5.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>Robert-Koch-Institut</collab>
</person-group><source>Bericht zur Epidemiologie der Tuberkulose in Deutschland f&#x000fc;r 2022</source><publisher-name>Robert-Koch-Institut</publisher-name><publisher-loc>Berlin, Germany</publisher-loc><year>2022</year><pub-id pub-id-type="doi">10.25646/11180</pub-id></element-citation></ref><ref id="B6-idr-17-00039"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jain</surname><given-names>R.</given-names></name>
<name><surname>Gupta</surname><given-names>G.</given-names></name>
<name><surname>Mitra</surname><given-names>D.K.</given-names></name>
<name><surname>Guleria</surname><given-names>R.</given-names></name>
</person-group><article-title>Diagnosis of extra pulmonary tuberculosis: An update on novel diagnostic approaches</article-title><source>Respir. Med.</source><year>2024</year><volume>225</volume><fpage>107601</fpage><pub-id pub-id-type="doi">10.1016/j.rmed.2024.107601</pub-id><pub-id pub-id-type="pmid">38513873</pub-id>
</element-citation></ref><ref id="B7-idr-17-00039"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Park</surname><given-names>M.</given-names></name>
<name><surname>Kon</surname><given-names>O.M.</given-names></name>
</person-group><article-title>Use of Xpert MTB/RIF and Xpert Ultra in extrapulmonary tuberculosis</article-title><source>Expert Rev. Anti-Infect. Ther.</source><year>2021</year><volume>19</volume><fpage>65</fpage><lpage>77</lpage><pub-id pub-id-type="doi">10.1080/14787210.2020.1810565</pub-id><pub-id pub-id-type="pmid">32806986</pub-id>
</element-citation></ref><ref id="B8-idr-17-00039"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shen</surname><given-names>Y.</given-names></name>
<name><surname>Fang</surname><given-names>L.</given-names></name>
<name><surname>Ye</surname><given-names>B.</given-names></name>
<name><surname>Yu</surname><given-names>G.</given-names></name>
</person-group><article-title>Meta-analysis of diagnostic accuracy of nucleic acid amplification tests for abdominal tuberculosis</article-title><source>PLoS ONE</source><year>2023</year><volume>18</volume><elocation-id>e0289336</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0289336</pub-id><pub-id pub-id-type="pmid">38011098</pub-id>
</element-citation></ref><ref id="B9-idr-17-00039"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>H.K.</given-names></name>
<name><surname>Liu</surname><given-names>R.S.</given-names></name>
<name><surname>Wang</surname><given-names>Y.X.</given-names></name>
<name><surname>Quan</surname><given-names>E.X.</given-names></name>
<name><surname>Liu</surname><given-names>Y.H.</given-names></name>
<name><surname>Guo</surname><given-names>X.G.</given-names></name>
</person-group><article-title>Xpert MTB/RIF Assay for the Diagnosis of Lymph Node Tuberculosis in Children: A Systematic Review and Meta-Analysis</article-title><source>J. Clin. Med.</source><year>2022</year><volume>11</volume><elocation-id>4616</elocation-id><pub-id pub-id-type="doi">10.3390/jcm11154616</pub-id><pub-id pub-id-type="pmid">35956230</pub-id>
</element-citation></ref><ref id="B10-idr-17-00039"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gong</surname><given-names>X.</given-names></name>
<name><surname>He</surname><given-names>Y.</given-names></name>
<name><surname>Zhou</surname><given-names>K.</given-names></name>
<name><surname>Hua</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
</person-group><article-title>Efficacy of Xpert in tuberculosis diagnosis based on various specimens: A systematic review and meta-analysis</article-title><source>Front. Cell Infect. Microbiol.</source><year>2023</year><volume>13</volume><elocation-id>1149741</elocation-id><pub-id pub-id-type="doi">10.3389/fcimb.2023.1149741</pub-id><pub-id pub-id-type="pmid">37201118</pub-id>
</element-citation></ref><ref id="B11-idr-17-00039"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kohli</surname><given-names>M.</given-names></name>
<name><surname>Schiller</surname><given-names>I.</given-names></name>
<name><surname>Dendukuri</surname><given-names>N.</given-names></name>
<name><surname>Yao</surname><given-names>M.</given-names></name>
<name><surname>Dheda</surname><given-names>K.</given-names></name>
<name><surname>Denkinger</surname><given-names>C.M.</given-names></name>
<name><surname>Schumacher</surname><given-names>S.G.</given-names></name>
<name><surname>Steingart</surname><given-names>K.R.</given-names></name>
</person-group><article-title>Xpert MTB/RIF Ultra and Xpert MTB/RIF assays for extrapulmonary tuberculosis and rifampicin resistance in adults</article-title><source>Cochrane Database Syst. Rev.</source><year>2021</year><volume>1</volume><fpage>CD012768</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD012768.pub3</pub-id><pub-id pub-id-type="pmid">33448348</pub-id>
</element-citation></ref><ref id="B12-idr-17-00039"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brown</surname><given-names>S.</given-names></name>
<name><surname>Leavy</surname><given-names>J.E.</given-names></name>
<name><surname>Jancey</surname><given-names>J.</given-names></name>
</person-group><article-title>Implementation of GeneXpert for TB Testing in Low- and Middle-Income Countries: A Systematic Review</article-title><source>Glob. Health Sci. Pract.</source><year>2021</year><volume>9</volume><fpage>698</fpage><lpage>710</lpage><pub-id pub-id-type="doi">10.9745/GHSP-D-21-00121</pub-id><pub-id pub-id-type="pmid">34593592</pub-id>
</element-citation></ref><ref id="B13-idr-17-00039"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yayan</surname><given-names>J.</given-names></name>
<name><surname>Rasche</surname><given-names>K.</given-names></name>
<name><surname>Franke</surname><given-names>K.J.</given-names></name>
<name><surname>Windisch</surname><given-names>W.</given-names></name>
<name><surname>Berger</surname><given-names>M.</given-names></name>
</person-group><article-title>FDG-PET-CT as an early detection method for tuberculosis: A systematic review and meta-analysis</article-title><source>BMC Public Health</source><year>2024</year><volume>24</volume><elocation-id>2022</elocation-id><pub-id pub-id-type="doi">10.1186/s12889-024-19495-6</pub-id><pub-id pub-id-type="pmid">39075378</pub-id>
</element-citation></ref><ref id="B14-idr-17-00039"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baykan</surname><given-names>A.H.</given-names></name>
<name><surname>Sayiner</surname><given-names>H.S.</given-names></name>
<name><surname>Aydin</surname><given-names>E.</given-names></name>
<name><surname>Koc</surname><given-names>M.</given-names></name>
<name><surname>Inan</surname><given-names>I.</given-names></name>
<name><surname>Erturk</surname><given-names>S.M.</given-names></name>
</person-group><article-title>Extrapulmonary tuberculosis: An old but resurgent problem</article-title><source>Insights Imaging</source><year>2022</year><volume>13</volume><fpage>39</fpage><pub-id pub-id-type="doi">10.1186/s13244-022-01172-0</pub-id><pub-id pub-id-type="pmid">35254534</pub-id>
</element-citation></ref><ref id="B15-idr-17-00039"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Tang</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>X.</given-names></name>
<name><surname>Cao</surname><given-names>M.</given-names></name>
<name><surname>Xiao</surname><given-names>Z.</given-names></name>
<name><surname>Ren</surname><given-names>M.</given-names></name>
<name><surname>Chen</surname><given-names>T.</given-names></name>
</person-group><article-title>Diagnostic performance of CT for differentiating peritoneal tuberculosis from peritoneal carcinomatosis: A systematic review and meta-analysis</article-title><source>Clin. Radiol.</source><year>2020</year><volume>75</volume><fpage>396.e7</fpage><lpage>396.e14</lpage><pub-id pub-id-type="doi">10.1016/j.crad.2019.12.014</pub-id><pub-id pub-id-type="pmid">32081347</pub-id>
</element-citation></ref><ref id="B16-idr-17-00039"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Baye</surname><given-names>N.</given-names></name>
<name><surname>Atnafu</surname><given-names>A.</given-names></name>
<name><surname>Girma</surname><given-names>S.</given-names></name>
<name><surname>Belete</surname><given-names>Y.</given-names></name>
<name><surname>Yimam</surname><given-names>S.</given-names></name>
<name><surname>Getachew</surname><given-names>B.</given-names></name>
<name><surname>Ayalew</surname><given-names>S.</given-names></name>
<name><surname>Bobosha</surname><given-names>K.</given-names></name>
<name><surname>Chanyalew</surname><given-names>Z.</given-names></name>
<name><surname>Gize</surname><given-names>A.</given-names></name>
<etal/>
</person-group><article-title>Evaluation of molecular and bacteriological detection methods performed on the formalin-fixed paraffin-embedded biopsy samples collected from endometrial and lymph node tuberculosis suspected patients</article-title><source>BMC Infect. Dis.</source><year>2024</year><volume>24</volume><elocation-id>1021</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-024-09908-7</pub-id><pub-id pub-id-type="pmid">39304809</pub-id>
</element-citation></ref><ref id="B17-idr-17-00039"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Afellah</surname><given-names>M.</given-names></name>
<name><surname>Zoukal</surname><given-names>S.</given-names></name>
<name><surname>Benmansour</surname><given-names>N.</given-names></name>
<name><surname>Arioua</surname><given-names>A.</given-names></name>
<name><surname>Ouattassi</surname><given-names>N.</given-names></name>
<name><surname>El Amine El Alami</surname><given-names>M.N.</given-names></name>
</person-group><article-title>The Performance of GeneXpert in the Diagnosis of Lymph Node Tuberculosis: A Prospective Study Comparing GeneXpert and Culture Findings</article-title><source>Cureus</source><year>2024</year><volume>16</volume><fpage>e64979</fpage><pub-id pub-id-type="doi">10.7759/cureus.64979</pub-id><pub-id pub-id-type="pmid">39161473</pub-id>
</element-citation></ref><ref id="B18-idr-17-00039"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Linh</surname><given-names>N.N.</given-names></name>
<name><surname>Viney</surname><given-names>K.</given-names></name>
<name><surname>Gegia</surname><given-names>M.</given-names></name>
<name><surname>Falzon</surname><given-names>D.</given-names></name>
<name><surname>Glaziou</surname><given-names>P.</given-names></name>
<name><surname>Floyd</surname><given-names>K.</given-names></name>
<name><surname>Timimi</surname><given-names>H.</given-names></name>
<name><surname>Ismail</surname><given-names>N.</given-names></name>
<name><surname>Zignol</surname><given-names>M.</given-names></name>
<name><surname>Kasaeva</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>World Health Organization treatment outcome definitions for tuberculosis: 2021 update</article-title><source>Eur. Respir. J.</source><year>2021</year><volume>58</volume><fpage>2100804</fpage><pub-id pub-id-type="doi">10.1183/13993003.00804-2021</pub-id><pub-id pub-id-type="pmid">34413124</pub-id>
</element-citation></ref><ref id="B19-idr-17-00039"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fernandova</surname><given-names>E.</given-names></name>
<name><surname>Bielakova</surname><given-names>K.</given-names></name>
<name><surname>Matejovska-Kubesova</surname><given-names>H.</given-names></name>
</person-group><article-title>Tuberculosis in elderly in the Czech Republic</article-title><source>Epidemiol. Mikrobiol. Imunol.</source><year>2019</year><volume>68</volume><fpage>184</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">31914775</pub-id>
</element-citation></ref><ref id="B20-idr-17-00039"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pape</surname><given-names>S.</given-names></name>
<name><surname>Karki</surname><given-names>S.J.</given-names></name>
<name><surname>Heinsohn</surname><given-names>T.</given-names></name>
<name><surname>Brandes</surname><given-names>I.</given-names></name>
<name><surname>Dierks</surname><given-names>M.L.</given-names></name>
<name><surname>Lange</surname><given-names>B.</given-names></name>
</person-group><article-title>Tuberculosis case fatality is higher in male than female patients in Europe: A systematic review and meta-analysis</article-title><source>Infection</source><year>2024</year><volume>52</volume><fpage>1775</fpage><lpage>1786</lpage><pub-id pub-id-type="doi">10.1007/s15010-024-02206-z</pub-id><pub-id pub-id-type="pmid">38521839</pub-id>
</element-citation></ref><ref id="B21-idr-17-00039"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schurz</surname><given-names>H.</given-names></name>
<name><surname>Salie</surname><given-names>M.</given-names></name>
<name><surname>Tromp</surname><given-names>G.</given-names></name>
<name><surname>Hoal</surname><given-names>E.G.</given-names></name>
<name><surname>Kinnear</surname><given-names>C.J.</given-names></name>
<name><surname>Moller</surname><given-names>M.</given-names></name>
</person-group><article-title>The X chromosome and sex-specific effects in infectious disease susceptibility</article-title><source>Hum. Genom.</source><year>2019</year><volume>13</volume><fpage>2</fpage><pub-id pub-id-type="doi">10.1186/s40246-018-0185-z</pub-id></element-citation></ref><ref id="B22-idr-17-00039"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>O&#x02019;Toole</surname><given-names>R.F.</given-names></name>
<name><surname>Shukla</surname><given-names>S.D.</given-names></name>
<name><surname>Walters</surname><given-names>E.H.</given-names></name>
</person-group><article-title>TB meets COPD: An emerging global co-morbidity in human lung disease</article-title><source>Tuberculosis</source><year>2015</year><volume>95</volume><fpage>659</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1016/j.tube.2015.08.005</pub-id><pub-id pub-id-type="pmid">26386744</pub-id>
</element-citation></ref><ref id="B23-idr-17-00039"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bergeron</surname><given-names>A.</given-names></name>
<name><surname>Mikulska</surname><given-names>M.</given-names></name>
<name><surname>De Greef</surname><given-names>J.</given-names></name>
<name><surname>Bondeelle</surname><given-names>L.</given-names></name>
<name><surname>Franquet</surname><given-names>T.</given-names></name>
<name><surname>Herrmann</surname><given-names>J.L.</given-names></name>
<name><surname>Lange</surname><given-names>C.</given-names></name>
<name><surname>Spriet</surname><given-names>I.</given-names></name>
<name><surname>Akova</surname><given-names>M.</given-names></name>
<name><surname>Donnelly</surname><given-names>J.P.</given-names></name>
<etal/>
</person-group><article-title>Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: Guidelines from the 8th European Conference on Infections in Leukaemia</article-title><source>Lancet Infect. Dis.</source><year>2022</year><volume>22</volume><fpage>e359</fpage><lpage>e369</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(22)00227-4</pub-id><pub-id pub-id-type="pmid">35636446</pub-id>
</element-citation></ref><ref id="B24-idr-17-00039"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>X.</given-names></name>
<name><surname>Pan</surname><given-names>X.</given-names></name>
<name><surname>Da</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>F.</given-names></name>
<name><surname>Dong</surname><given-names>Z.</given-names></name>
</person-group><article-title>Risk for latent tuberculosis infection reactivation among patients with psoriasis on biologics treatment: A meta-analysis</article-title><source>J. Infect.</source><year>2024</year><volume>89</volume><fpage>106226</fpage><pub-id pub-id-type="doi">10.1016/j.jinf.2024.106226</pub-id><pub-id pub-id-type="pmid">38986747</pub-id>
</element-citation></ref><ref id="B25-idr-17-00039"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chauhan</surname><given-names>A.</given-names></name>
<name><surname>Parmar</surname><given-names>M.</given-names></name>
<name><surname>Dash</surname><given-names>G.</given-names></name>
<name><surname>Solanki</surname><given-names>H.</given-names></name>
<name><surname>Chauhan</surname><given-names>S.</given-names></name>
<name><surname>Sahoo</surname><given-names>K.C.</given-names></name>
<name><surname>Vadera</surname><given-names>B.</given-names></name>
<name><surname>Rao</surname><given-names>R.</given-names></name>
<name><surname>Kumar</surname><given-names>R.</given-names></name>
<name><surname>Rade</surname><given-names>K.</given-names></name>
<etal/>
</person-group><article-title>Prevalence of Tuberculosis Infection Among Various Risk Groups in India: A Systematic Review and Meta-Analysis</article-title><source>Indian. J. Community Med.</source><year>2024</year><volume>49</volume><fpage>669</fpage><lpage>680</lpage><pub-id pub-id-type="doi">10.4103/ijcm.ijcm_36_24</pub-id><pub-id pub-id-type="pmid">39421504</pub-id>
</element-citation></ref><ref id="B26-idr-17-00039"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Saleem</surname><given-names>U.A.</given-names></name>
<name><surname>Karimi</surname><given-names>A.S.</given-names></name>
<name><surname>Ehsan</surname><given-names>H.</given-names></name>
</person-group><article-title>A Systematic Review on Pulmonary TB Burden and Associated Factors Among Immigrants in the UK</article-title><source>Infect. Drug Resist.</source><year>2023</year><volume>16</volume><fpage>7835</fpage><lpage>7853</lpage><pub-id pub-id-type="doi">10.2147/IDR.S441536</pub-id><pub-id pub-id-type="pmid">38162319</pub-id>
</element-citation></ref><ref id="B27-idr-17-00039"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Franco</surname><given-names>J.V.</given-names></name>
<name><surname>Bongaerts</surname><given-names>B.</given-names></name>
<name><surname>Metzendorf</surname><given-names>M.I.</given-names></name>
<name><surname>Risso</surname><given-names>A.</given-names></name>
<name><surname>Guo</surname><given-names>Y.</given-names></name>
<name><surname>Pena Silva</surname><given-names>L.</given-names></name>
<name><surname>Boeckmann</surname><given-names>M.</given-names></name>
<name><surname>Schlesinger</surname><given-names>S.</given-names></name>
<name><surname>Damen</surname><given-names>J.A.</given-names></name>
<name><surname>Richter</surname><given-names>B.</given-names></name>
<etal/>
</person-group><article-title>Diabetes as a risk factor for tuberculosis disease</article-title><source>Cochrane Database Syst. Rev.</source><year>2024</year><volume>8</volume><fpage>CD016013</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD016013.pub2</pub-id><pub-id pub-id-type="pmid">39177079</pub-id>
</element-citation></ref><ref id="B28-idr-17-00039"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kibirige</surname><given-names>D.</given-names></name>
<name><surname>Andia-Biraro</surname><given-names>I.</given-names></name>
<name><surname>Kyazze</surname><given-names>A.P.</given-names></name>
<name><surname>Olum</surname><given-names>R.</given-names></name>
<name><surname>Bongomin</surname><given-names>F.</given-names></name>
<name><surname>Nakavuma</surname><given-names>R.M.</given-names></name>
<name><surname>Ssekamatte</surname><given-names>P.</given-names></name>
<name><surname>Emoru</surname><given-names>R.</given-names></name>
<name><surname>Nalubega</surname><given-names>G.</given-names></name>
<name><surname>Chamba</surname><given-names>N.</given-names></name>
<etal/>
</person-group><article-title>Burden and associated phenotypic characteristics of tuberculosis infection in adult Africans with diabetes: A systematic review</article-title><source>Sci. Rep.</source><year>2023</year><volume>13</volume><elocation-id>19894</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-023-47285-4</pub-id><pub-id pub-id-type="pmid">37963989</pub-id>
</element-citation></ref><ref id="B29-idr-17-00039"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tahseen</surname><given-names>S.</given-names></name>
<name><surname>Khanzada</surname><given-names>F.M.</given-names></name>
<name><surname>Baloch</surname><given-names>A.Q.</given-names></name>
<name><surname>Abbas</surname><given-names>Q.</given-names></name>
<name><surname>Bhutto</surname><given-names>M.M.</given-names></name>
<name><surname>Alizai</surname><given-names>A.W.</given-names></name>
<name><surname>Zaman</surname><given-names>S.</given-names></name>
<name><surname>Qasim</surname><given-names>Z.</given-names></name>
<name><surname>Durrani</surname><given-names>M.N.</given-names></name>
<name><surname>Farough</surname><given-names>M.K.</given-names></name>
<etal/>
</person-group><article-title>Extrapulmonary tuberculosis in Pakistan- A nation-wide multicenter retrospective study</article-title><source>PLoS ONE</source><year>2020</year><volume>15</volume><elocation-id>e0232134</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0232134</pub-id><pub-id pub-id-type="pmid">32343714</pub-id>
</element-citation></ref><ref id="B30-idr-17-00039"><label>30.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>WHO</collab>
</person-group><source>Global Tuberculosis Report 2019</source><publisher-name>World Health Organization</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2019</year><isbn>978-92-4-156571-4</isbn></element-citation></ref><ref id="B31-idr-17-00039"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Forssbohm</surname><given-names>M.</given-names></name>
<name><surname>Zwahlen</surname><given-names>M.</given-names></name>
<name><surname>Loddenkemper</surname><given-names>R.</given-names></name>
<name><surname>Rieder</surname><given-names>H.L.</given-names></name>
</person-group><article-title>Demographic characteristics of patients with extrapulmonary tuberculosis in Germany</article-title><source>Eur. Respir. J.</source><year>2008</year><volume>31</volume><fpage>99</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1183/09031936.00020607</pub-id><pub-id pub-id-type="pmid">17804450</pub-id>
</element-citation></ref><ref id="B32-idr-17-00039"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sandgren</surname><given-names>A.</given-names></name>
<name><surname>Hollo</surname><given-names>V.</given-names></name>
<name><surname>van der Werf</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Extrapulmonary tuberculosis in the European Union and European Economic Area, 2002 to 2011</article-title><source>Euro Surveill.</source><year>2013</year><volume>18</volume><fpage>20431</fpage><pub-id pub-id-type="doi">10.2807/ese.18.12.20431-en</pub-id><pub-id pub-id-type="pmid">23557943</pub-id>
</element-citation></ref><ref id="B33-idr-17-00039"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guler</surname><given-names>S.A.</given-names></name>
<name><surname>Bozkus</surname><given-names>F.</given-names></name>
<name><surname>Inci</surname><given-names>M.F.</given-names></name>
<name><surname>Kokoglu</surname><given-names>O.F.</given-names></name>
<name><surname>Ucmak</surname><given-names>H.</given-names></name>
<name><surname>Ozden</surname><given-names>S.</given-names></name>
<name><surname>Yuksel</surname><given-names>M.</given-names></name>
</person-group><article-title>Evaluation of pulmonary and extrapulmonary tuberculosis in immunocompetent adults: A retrospective case series analysis</article-title><source>Med. Princ. Pract.</source><year>2015</year><volume>24</volume><fpage>75</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1159/000365511</pub-id><pub-id pub-id-type="pmid">25341702</pub-id>
</element-citation></ref><ref id="B34-idr-17-00039"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sunnetcioglu</surname><given-names>A.</given-names></name>
<name><surname>Sunnetcioglu</surname><given-names>M.</given-names></name>
<name><surname>Binici</surname><given-names>I.</given-names></name>
<name><surname>Baran</surname><given-names>A.I.</given-names></name>
<name><surname>Karahocagil</surname><given-names>M.K.</given-names></name>
<name><surname>Saydan</surname><given-names>M.R.</given-names></name>
</person-group><article-title>Comparative analysis of pulmonary and extrapulmonary tuberculosis of 411 cases</article-title><source>Ann. Clin. Microbiol. Antimicrob.</source><year>2015</year><volume>14</volume><elocation-id>34</elocation-id><pub-id pub-id-type="doi">10.1186/s12941-015-0092-2</pub-id><pub-id pub-id-type="pmid">26104066</pub-id>
</element-citation></ref><ref id="B35-idr-17-00039"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Niu</surname><given-names>T.</given-names></name>
<name><surname>Li</surname><given-names>Y.</given-names></name>
<name><surname>Ru</surname><given-names>C.</given-names></name>
<name><surname>Chen</surname><given-names>A.</given-names></name>
<name><surname>Shi</surname><given-names>Y.</given-names></name>
<name><surname>Lu</surname><given-names>S.</given-names></name>
<name><surname>Han</surname><given-names>J.</given-names></name>
<name><surname>Yu</surname><given-names>X.</given-names></name>
<name><surname>Zhong</surname><given-names>C.</given-names></name>
<name><surname>Shen</surname><given-names>Y.</given-names></name>
<etal/>
</person-group><article-title>Analysis of the prevalence characteristics and risk factors of pulmonary tuberculosis combined with extrapulmonary tuberculosis in elderly patients</article-title><source>Sci. Rep.</source><year>2024</year><volume>14</volume><elocation-id>25870</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-024-76887-9</pub-id><pub-id pub-id-type="pmid">39468235</pub-id>
</element-citation></ref><ref id="B36-idr-17-00039"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lee</surname><given-names>M.K.</given-names></name>
<name><surname>Moon</surname><given-names>C.</given-names></name>
<name><surname>Lee</surname><given-names>M.J.</given-names></name>
<name><surname>Kwak</surname><given-names>Y.G.</given-names></name>
<name><surname>Lee</surname><given-names>E.</given-names></name>
<name><surname>Jeon</surname><given-names>J.H.</given-names></name>
<name><surname>Park</surname><given-names>W.B.</given-names></name>
<name><surname>Jung</surname><given-names>Y.</given-names></name>
<name><surname>Kim</surname><given-names>E.S.</given-names></name>
<name><surname>Lee</surname><given-names>J.H.</given-names></name>
<etal/>
</person-group><article-title>Risk factors for the delayed diagnosis of extrapulmonary TB</article-title><source>Int. J. Tuberc. Lung Dis.</source><year>2021</year><volume>25</volume><fpage>191</fpage><lpage>198</lpage><pub-id pub-id-type="doi">10.5588/ijtld.20.0788</pub-id><pub-id pub-id-type="pmid">33688807</pub-id>
</element-citation></ref><ref id="B37-idr-17-00039"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>J.H.</given-names></name>
<name><surname>Kim</surname><given-names>E.S.</given-names></name>
<name><surname>Jun</surname><given-names>K.I.</given-names></name>
<name><surname>Jung</surname><given-names>H.G.</given-names></name>
<name><surname>Bang</surname><given-names>J.H.</given-names></name>
<name><surname>Choe</surname><given-names>P.G.</given-names></name>
<name><surname>Park</surname><given-names>W.B.</given-names></name>
<name><surname>Song</surname><given-names>K.H.</given-names></name>
<name><surname>Kim</surname><given-names>H.B.</given-names></name>
<name><surname>Kim</surname><given-names>N.J.</given-names></name>
<etal/>
</person-group><article-title>Delayed diagnosis of extrapulmonary tuberculosis presenting as fever of unknown origin in an intermediate-burden country</article-title><source>BMC Infect. Dis.</source><year>2018</year><volume>18</volume><elocation-id>426</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-018-3349-5</pub-id><pub-id pub-id-type="pmid">30153813</pub-id>
</element-citation></ref><ref id="B38-idr-17-00039"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bell</surname><given-names>L.C.</given-names></name>
<name><surname>Breen</surname><given-names>R.</given-names></name>
<name><surname>Miller</surname><given-names>R.F.</given-names></name>
<name><surname>Noursadeghi</surname><given-names>M.</given-names></name>
<name><surname>Lipman</surname><given-names>M.</given-names></name>
</person-group><article-title>Paradoxical reactions and immune reconstitution inflammatory syndrome in tuberculosis</article-title><source>Int. J. Infect. Dis.</source><year>2015</year><volume>32</volume><fpage>39</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2014.12.030</pub-id><pub-id pub-id-type="pmid">25809754</pub-id>
</element-citation></ref><ref id="B39-idr-17-00039"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Singh</surname><given-names>A.K.</given-names></name>
<name><surname>Malhotra</surname><given-names>H.S.</given-names></name>
<name><surname>Garg</surname><given-names>R.K.</given-names></name>
<name><surname>Jain</surname><given-names>A.</given-names></name>
<name><surname>Kumar</surname><given-names>N.</given-names></name>
<name><surname>Kohli</surname><given-names>N.</given-names></name>
<name><surname>Verma</surname><given-names>R.</given-names></name>
<name><surname>Sharma</surname><given-names>P.K.</given-names></name>
</person-group><article-title>Paradoxical reaction in tuberculous meningitis: Presentation, predictors and impact on prognosis</article-title><source>BMC Infect. Dis.</source><year>2016</year><volume>16</volume><elocation-id>306</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-016-1625-9</pub-id><pub-id pub-id-type="pmid">27329253</pub-id>
</element-citation></ref><ref id="B40-idr-17-00039"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Narendran</surname><given-names>G.</given-names></name>
<name><surname>Jyotheeswaran</surname><given-names>K.</given-names></name>
<name><surname>Senguttuvan</surname><given-names>T.</given-names></name>
<name><surname>Vinhaes</surname><given-names>C.L.</given-names></name>
<name><surname>Santhanakrishnan</surname><given-names>R.K.</given-names></name>
<name><surname>Manoharan</surname><given-names>T.</given-names></name>
<name><surname>Selvaraj</surname><given-names>A.</given-names></name>
<name><surname>Chandrasekaran</surname><given-names>P.</given-names></name>
<name><surname>Menon</surname><given-names>P.A.</given-names></name>
<name><surname>Bhavani</surname><given-names>K.P.</given-names></name>
<etal/>
</person-group><article-title>Characteristics of paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome and its influence on tuberculosis treatment outcomes in persons living with HIV</article-title><source>Int. J. Infect. Dis.</source><year>2020</year><volume>98</volume><fpage>261</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2020.06.097</pub-id><pub-id pub-id-type="pmid">32623087</pub-id>
</element-citation></ref><ref id="B41-idr-17-00039"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Denkinger</surname><given-names>C.M.</given-names></name>
<name><surname>Schumacher</surname><given-names>S.G.</given-names></name>
<name><surname>Boehme</surname><given-names>C.C.</given-names></name>
<name><surname>Dendukuri</surname><given-names>N.</given-names></name>
<name><surname>Pai</surname><given-names>M.</given-names></name>
<name><surname>Steingart</surname><given-names>K.R.</given-names></name>
</person-group><article-title>Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: A systematic review and meta-analysis</article-title><source>Eur. Respir. J.</source><year>2014</year><volume>44</volume><fpage>435</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1183/09031936.00007814</pub-id><pub-id pub-id-type="pmid">24696113</pub-id>
</element-citation></ref><ref id="B42-idr-17-00039"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Scott</surname><given-names>L.E.</given-names></name>
<name><surname>Beylis</surname><given-names>N.</given-names></name>
<name><surname>Nicol</surname><given-names>M.</given-names></name>
<name><surname>Nkuna</surname><given-names>G.</given-names></name>
<name><surname>Molapo</surname><given-names>S.</given-names></name>
<name><surname>Berrie</surname><given-names>L.</given-names></name>
<name><surname>Duse</surname><given-names>A.</given-names></name>
<name><surname>Stevens</surname><given-names>W.S.</given-names></name>
</person-group><article-title>Diagnostic accuracy of Xpert MTB/RIF for extrapulmonary tuberculosis specimens: Establishing a laboratory testing algorithm for South Africa</article-title><source>J. Clin. Microbiol.</source><year>2014</year><volume>52</volume><fpage>1818</fpage><lpage>1823</lpage><pub-id pub-id-type="doi">10.1128/JCM.03553-13</pub-id><pub-id pub-id-type="pmid">24622091</pub-id>
</element-citation></ref><ref id="B43-idr-17-00039"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kohli</surname><given-names>M.</given-names></name>
<name><surname>Schiller</surname><given-names>I.</given-names></name>
<name><surname>Dendukuri</surname><given-names>N.</given-names></name>
<name><surname>Dheda</surname><given-names>K.</given-names></name>
<name><surname>Denkinger</surname><given-names>C.M.</given-names></name>
<name><surname>Schumacher</surname><given-names>S.G.</given-names></name>
<name><surname>Steingart</surname><given-names>K.R.</given-names></name>
</person-group><article-title>Xpert<sup>&#x000ae;</sup> MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance</article-title><source>Cochrane Database Syst. Rev.</source><year>2018</year><volume>8</volume><fpage>CD012768</fpage><pub-id pub-id-type="doi">10.1002/14651858.CD012768.pub2</pub-id><pub-id pub-id-type="pmid">30148542</pub-id>
</element-citation></ref></ref-list></back><floats-group><table-wrap position="float" id="idr-17-00039-t001"><object-id pub-id-type="pii">idr-17-00039-t001_Table 1</object-id><label>Table 1</label><caption><p>Patient&#x02019;s characteristics: MDR = multi-drug resistant, XDR = extended drug resistant; ** for details, see <xref rid="app1-idr-17-00039" ref-type="app">Supplemental Table S1</xref>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="3" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Patient Characteristics (<italic toggle="yes">n</italic> = 194)</th></tr></thead><tbody><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">General characteristics</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age, years, median (min, max)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41 (16&#x02013;89)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gender, male, total (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">121 (62.4%)</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Country of origin, absolute (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Germany</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50 (25.8)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Other than Germany **</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">144 (74.2)</td></tr><tr><td rowspan="6" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">WHO geographic regions of origin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Europe</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93 (47.9%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Africa</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34 (17.5%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Eastern Mediterranean</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32 (16.5%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Southeast Asia</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18 (9.3) </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Americas</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (1%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Unknown</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15 (7.7%)</td></tr><tr><td rowspan="10" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Pre-existing conditions,<break/>absolute (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diabetes mellitus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19 (9.8%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cardiac disease</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">42 (21.6%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pulmonary disease</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28 (14.4%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV infection</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18 (9.3)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Replicating hepatitis C infection</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (4.1)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Replicating hepatitis B infection</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (2.6)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Solid organ transplantation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (3.6)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hematologic disease</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (3.1)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Autoimmune disease</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16 (8.2)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunosuppressive therapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">36 (18.6)</td></tr><tr><td rowspan="10" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Site of TB infection, absolute (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Isolated pulmonary manifestation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98 (50.5%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Disseminated infection (more than one site of inception)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41 (21.1%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lymph node</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31 (16%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bone and joint</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (5.2%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Abdominal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (2.6%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Urogenital</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (1%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Intestinal</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (1%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cardiac</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (1%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Soft tissue</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (1%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cerebral/meningitis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (0.5%)</td></tr><tr><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Tuberculosis drug resistance, absolute (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MDR tuberculosis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (5.2)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pre-XDR tuberculosis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (1.5)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">XDR tuberculosis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (1.5)</td></tr><tr><td rowspan="4" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Therapy outcome</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not evaluated (lost to follow-up)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">119 (61.3)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Sustained treatment success</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55 (28.4%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Deceased</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (1.5%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Therapy ongoing</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">17 (8.8%)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="idr-17-00039-t002"><object-id pub-id-type="pii">idr-17-00039-t002_Table 2</object-id><label>Table 2</label><caption><p>Comparative analysis between patients with isolated pulmonary tuberculosis and those with extrapulmonary/disseminated tuberculosis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Isolated Pulmonary Tuberculosis (<italic toggle="yes">n</italic> = 98)</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Extrapulmonary/Disseminated Tuberculosis (<italic toggle="yes">n</italic> = 96)</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1"><italic toggle="yes">p</italic>-Value</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Age, years, median (min&#x02013;max)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44.5 (16&#x02013;85)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">35 (18&#x02013;89)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Gender, male, total (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">66 (67.3%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55 (57.3%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.15</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Country of origin Germany, absolute (%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">31 (31.6%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19 (19.7%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.049</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Symptomatic disease</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">64 (65.3%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">82 (85.4%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Diagnosed through contact tracing</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">34 (34.7%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">14 (14.6%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Time interval from first physician contact until TB diagnosis (weeks), median (min&#x02013;max)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1&#x02013;8)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1&#x02013;208)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.013</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Detection of drug resistance (PCR and/or culture)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16 (16.3%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18 (18.8%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.66</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TB diagnosis (Smear)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">98 (100%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">96 (100%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n.d.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x000a0;Microscopy positive</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40 (40.8%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (13.5%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x000a0;Positive MTB NAAT </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">73 (74.5%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">28 (29.2%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x000a0;Culture positive</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68 (69.4%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 (26.0%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Disease-associated complications </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16 (16.3%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">41 (42.7%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x000a0;Hepatotoxic side effect of tuberculostatic medication</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (4.1%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (10.4%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x000a0;Hemoptysis </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (2%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x000a0;Pancreatitis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 0%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (2.1%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x000a0;Ileus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x000a0;TBC bacteriaemia</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (2%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (9.4%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.03</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x000a0;Paradoxical immune reaction</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (8.3%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x000a0;Required surgery</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">11 (11.5%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x000a0;Hemophagocytic lymphohistiocytosis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (2.1%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Organ transplantation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (5.1)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (2.1%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.45</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hematologic disease</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (4.1%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (2.1%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Autoimmune disease</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (8.2%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (8.3%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immunosuppressive therapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18 (18.4)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18 (18.8)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.95</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">HIV infection</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (10.2%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (8.3%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.81</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD4<sup>+</sup> cell count (cells/&#x000b5;L) (IQR)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">264.0 (84.75&#x02013;442.0)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">126.5 (44.25&#x02013;225.75)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.21</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Antiretroviral therapy</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 (60%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (12.5%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.04</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hep. C infection</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (7.1%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 (5.2%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n.d.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hep. C RNA detectable</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (57.1%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (80%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n.d. </td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hep. B infection</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (8.2%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">12 (12.5%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n.d.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hep. B DNA detectable</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (12.5%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (33%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">n.d.</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Drug resistance </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">16 (16.3%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">18 (18.8%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.66</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TBC medical treatment</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">95 (96.9%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">93 (96.9)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.0</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x000a0;Standard treatment (Rif, Iso, PZA, Etb)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">74 (75.5%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">71 (74%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Therapy outcome</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.24</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x000a0;Not evaluated (Lost to follow-up)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">65 (66.3%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">53 (55.2%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x000a0;Sustained Treatment Success</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">23 (23.5%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">32 (33.3%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x000a0;Deceased</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (3.1%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (1%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x000a0;Therapy ongoing</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7 (7.1%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 (10.4%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table></table-wrap><table-wrap position="float" id="idr-17-00039-t003"><object-id pub-id-type="pii">idr-17-00039-t003_Table 3</object-id><label>Table 3</label><caption><p>Table summarizing diagnostic tests and outcomes for extrapulmonary/disseminated tuberculosis (<italic toggle="yes">n</italic> = 92), including multiple procedural requirements, biopsy distribution, histology, TBC culture, and NAAT on formalin-fixed and native specimens.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">
</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Extrapulmonary/Disseminated Tuberculosis (<italic toggle="yes">n</italic> = 92)</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">More than one procedure is required for microbiological pathogen confirmation</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40 (43.5%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Histological analysis</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">68 (73.9%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x000a0;Detection of epithelioid granulomas</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59 (86.8%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NAAT on formalin-fixed specimens</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">55 (59.8%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x000a0;NAAT positive for MTB DNA </td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">44 (80%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TB culture done</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78 (84.8%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x000a0;TBC culture positive</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">56 (71.8%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Microscopic analysis on native (no formalin fixation) specimens</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78 (84.8%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x000a0;Detection of acid-fast bacilli</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">22 (28.2%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NAAT on native (no formalin fixation) specimens</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78 (84.8%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x000a0;NAAT positive for MTB DNA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">59 (75.6%)</td></tr></tbody></table></table-wrap><table-wrap position="float" id="idr-17-00039-t004"><object-id pub-id-type="pii">idr-17-00039-t004_Table 4</object-id><label>Table 4</label><caption><p>Comparison of tuberculosis (TBC) culture status between various specimen types in EPTB patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Specimen</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">MTB Culture Positive</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">PCR Primary Specimen Positive</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Microscopy Primary Specimen Positive</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lymph node (<italic toggle="yes">n</italic> = 31)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">24 (77.4%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">27 (87.1%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (25.8%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bone biopsy (<italic toggle="yes">n</italic> = 15)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">13 (86.7%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9 (60%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (26.7%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Soft tissue biopsy (<italic toggle="yes">n</italic> = 8)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (50%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8 (100%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (50%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Colon biopsy (<italic toggle="yes">n</italic> = 5)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (60%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (80%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (40%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Bone marrow biopsy (<italic toggle="yes">n</italic> = 2)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (50%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Brain biopsy (<italic toggle="yes">n</italic> = 4)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (25%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (50%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Urine (<italic toggle="yes">n</italic> = 4)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (100%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 (100%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 (75%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stool (<italic toggle="yes">n</italic> = 2)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (50%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liver biopsy (<italic toggle="yes">n</italic> = 2)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (50%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ascites (<italic toggle="yes">n</italic> = 1)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (100%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (100%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Blood culture (<italic toggle="yes">n</italic> = 2)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (100%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (100%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Pericard (<italic toggle="yes">n</italic> = 2)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 (100%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 (50%)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0 (0%)</td></tr></tbody></table></table-wrap></floats-group></article>